Full-Time

Director – Shared Antigen Cancer Vaccines

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines and therapies

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

70% in-office presence required.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • PhD in biology, immunology, virology, or related areas of study.
  • Minimum of 10+ years of immune oncology discovery/drug development experience after postdoctoral training.
  • A record of innovation and research accomplishments in translating cancer therapeutics from preclinical to clinical setting.
  • Substantial experience in design and execution of early stage research program(s) to identify and validate novel targets in immune-oncology.
  • Familiarity with classes of shared tumor antigens and fluency in methods to identify, validate, and functionally test functionality as a cancer vaccine.
  • Extensive knowledge of cancer vaccine biology, murine tumor models, and immunological assays (human and non-human).
  • People management experience including a history of developing reports.
  • Familiarity with emergent and current standards of care to help define treatment settings, rational combinations, including with cancer vaccines to interrogate pre-clinically.
  • Ability to effectively collaborate in a dynamic, cross-functional matrixed environment.
  • Proven ability to manage multiple projects in a fast-paced environment, prioritize work and meet tight timelines.
  • Ability to focus and prioritize work that aligns with cancer vaccine program and organizational objectives.
  • Innovative approach to addressing drug development challenges, with scientific versatility and flexibility.
  • Exceptional organizational skills and excellent attention to detail.
  • Committed to fostering a respectful, inclusive, creative and curious work environment.
  • A desire to make an impact on human health as part of a high-growth, transformational company that is Bold, Relentless, Curious, and Collaborative.
Responsibilities
  • Work cross-functionally with teams across Moderna (Strategy, Research, Manufacturing/Technical Development, Regulatory, and Clinical) to conceive of shared antigen-targeting vaccine concepts and accelerate their pre-clinical development.
  • Lead an experimental team of scientists to orchestrate the design and execution of pre-clinical tests that contribute to IND filings and support new programs.
  • Advance discovery work flows for new Shared Antigen vaccine programs.
  • Manage program deliverables and timelines, and coordinate cross-functional teams to efficiently generate IND-enabling data sets.
  • Lead and mentor a team of scientists, developing both managers and individual contributors.
  • Present team findings at internal and external meetings in the form of scientific abstracts, posters, presentations, or manuscripts.
  • Liaise and collaborate with internal and external research groups.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a molecule that provides instructions for cells to produce proteins essential for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially enhance the discovery, development, and manufacturing of drugs. Unlike traditional methods, which often rely on proteins or other biological materials, Moderna's use of mRNA allows for a more versatile and efficient way to create treatments. The company's goal is to improve patient outcomes by harnessing the power of mRNA to address a wide range of health issues.

Company Stage

Grant

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

N/A

Growth & Insights
Headcount

6 month growth

3%

1 year growth

12%

2 year growth

54%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's expansion into combination vaccines and autoimmune therapies showcases its potential for diversified revenue streams and market leadership.
  • The company's continuous innovation and FDA approvals for updated COVID-19 vaccines highlight its resilience and adaptability in a rapidly changing market.
  • Moderna's educational initiatives, like the free mRNA course, position it as a thought leader and advocate for mRNA technology.

What critics are saying

  • The collapse in demand for COVID-19 vaccines could significantly impact Moderna's revenue and growth prospects.
  • Ongoing class action lawsuits alleging securities fraud could damage Moderna's reputation and financial stability.

What makes Moderna unique

  • Moderna is pioneering the use of mRNA technology to create a new class of medicines, setting it apart from traditional pharmaceutical companies.
  • The company's focus on mRNA as the 'software of life' allows for rapid development and manufacturing of vaccines and therapies, unlike conventional methods.
  • Moderna's ability to secure regulatory approvals for mRNA vaccines beyond COVID-19, such as for RSV, demonstrates its leadership in mRNA technology.

Help us improve and share your feedback! Did you find this helpful?